Indole compounds, a process for their preparation and pharmaceutical compositions containing them.
AssigneeLes Laboratories Servier
InventorsPascal Marchand, Vincent Babonneau, Sylvie Piessard, Muriel Duflos, Jean Albert, Valerie Audinot, Philippe Delagrange, Daniel-Henri Caignard
Life of this patent
Estimating the term…
Abstract
Compounds of formula (I): wherein: R1 represents an alkyl, cycloalkyl or cycloalkylalkyl group, R2 represents a linear or branched (C1-C6)alkyl group, and n represents from 1 to 6.
Claims11
1-11. (canceled)
12- A compound selected from those of formula (I):
- wherein:
- R1 represents a linear or branched (C1-C6)alkyl group, a linear or branched (C3-C8)-cycloalkyl group or a (C3-C8)cycloalkyl-(C1-C6)alkyl group in which the alkyl moiety may be linear or branched,
- R2 represents a linear or branched (C1-C6)alkyl group,
- and n represents 1, 2, 3, 4, 5 or 6,
- its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.)
13- The compound of claim 12, wherein n represents 2.
14- The compound of claim 12, wherein R1 represents a methyl group.
15- The compound of claim 12, wherein R2 represents a methyl, ethyl or propyl group.)
16- The compound of claim 12 which is 1-[2-(acetylamino)ethyl]-6-methoxy-N-methyl-1H-indole-2-carboxamide, or an addition salt thereof with a pharmaceutically acceptable acid or base.
17- The compound of claim 12 which is 1-[2-(acetylamino)ethyl]-N-ethyl-6-methoxy-1H-indole-2-carboxamide, or an addition salt thereof with a pharmaceutically acceptable acid or base.)
18- The compound of claim 12 which is 1-[2-(acetylamino)ethyl]-6-methoxy-N-propyl-1H-indole-2-carboxamide, or an addition salt thereof with a pharmaceutically acceptable acid or base.
19- A pharmaceutical composition comprising at least one compound of claim 12, or an addition salt thereof with a pharmaceutically acceptable acid or base, in combination with one or more pharmaceutically acceptable excipients.
20- A method for treating a living animal body, including a human, afflicted with a disorder of the melatoninergic system, comprising the step of administering to the living animal body, including a human, a therapeutically effective amount of the compound of claim 12.
21- A method for treating a living animal body, including a human, afflicted with a condition selected from sleep disorders, stress, anxiety, major depression or seasonal affective disorder, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to jetlag, schizophrenia, panic attacks, melancholia, appetite disorders, obesity, insomnia, psychotic disorders, epilepsy, diabetes, Parkinson's disease, senile dementia, disorders associated with normal or pathological aging, migraine, memory loss, Alzheimer's disease, cerebral circulation disorders, sexual dysfunction, a condition requiring an ovulation inhibitor, a condition requiring an immunomodulator, and cancer, comprising the step of administering to the living animal body, including a human, a therapeutically effective amount of the compound of claim 12.